Dalpiciclib plus camrelizumab for liver cancer after immunotherapy
Treatments studied
Part of Cancer clinical trials.
This trial tests two drugs, dalpiciclib and camrelizumab, for people with advanced liver cancer (stage C) whose cancer has grown despite previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (stage C) that cannot be removed with surgery.
- You have received at least one prior immunotherapy treatment (like a PD-1 or PD-L1 inhibitor) and your cancer got worse.
- You have a good activity level (up and about, able to care for yourself).
- Your liver is in relatively good condition (no major scarring or serious complications like fluid in the belly or bleeding).
- Your blood counts and organ function are within certain safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial tests whether combining two drugs, camrelizumab (an immunotherapy) and apatinib (a targeted therapy), can prevent liver cancer from coming back in people who've had surgery or ablation to remove their tumor. It's for patients with a high risk of recurrence.
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
This trial tests a combination of chemotherapy (mFOLFOX7) plus two targeted/immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer that has grown beyond standard transplant criteria. It aims to shrink tumors and improve outcomes.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Hear when a new Hepatocellulcar Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.